Trial Profile
A Double-blind, Placebo-controlled, Randomized Trial Investigating the Safety and Efficacy of Additive Renin Inhibition With Aliskiren on Renal Blood Flow and Neurohormonal Activation in Patients With Chronic Heart Failure and Renal Dysfunction
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Aliskiren (Primary)
- Indications Heart failure
- Focus Pharmacodynamics
- Acronyms ARIANA-CHF-RD
- 01 May 2015 Results published in the American Heart Journal.
- 16 Apr 2009 New trial record